{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:45:47Z","timestamp":1795023947239,"version":"4.10.2"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:p>The combination of mRNA and lncRNA profiles for establishing an integrated mRNA\u2013lncRNA prognostic signature has remained unexplored in cholangiocarcinoma (CCA) patients. We utilized a training dataset of 36 samples from The Cancer Genome Atlas dataset and a validation cohort (GSE107943) of 30 samples from Gene Expression Omnibus. Two mRNAs (<jats:italic toggle=\"yes\">CFHR3<\/jats:italic> and <jats:italic toggle=\"yes\">PIWIL4<\/jats:italic>) and 2 lncRNAs (<jats:italic toggle=\"yes\">AC007285.1<\/jats:italic> and <jats:italic toggle=\"yes\">AC134682.1<\/jats:italic>) were identified to construct the integrated signature through a univariate Cox regression (<jats:italic toggle=\"yes\">P<\/jats:italic>-value\u2005=\u20051.35E\u221202) and a multivariable Cox analysis (<jats:italic toggle=\"yes\">P<\/jats:italic>-value\u2005=\u20053.07E\u221202). Kaplan\u2013Meier curve showed that patients with low risk scores had notably prolonged overall survival than those with high risk scores (<jats:italic toggle=\"yes\">P<\/jats:italic>-value\u2005=\u20054.61E\u221203). Subsequently, the signature was validated in GSE107943 cohort with an area under the curve of 0.750 at 1-year and 0.729 at 3-year. The signature was not only independent from diverse clinical features (<jats:italic toggle=\"yes\">P<\/jats:italic>-value\u2005=\u20053.07E\u221202), but also surpassed other clinical characteristics as prognostic biomarkers with area under the curve of 0.781 at 3-year. Moreover, the weighted gene co-expression network analysis and gene enrichment analyses found that the integrated signature were associated with metabolic-related biological process and lipid metabolism pathway, which has been implicated in the pathogenesis of CCA. Taken together, we developed an integrated mRNA\u2013lncRNA signature that had an independent prognostic value in the risk stratification of patients with CCA.<\/jats:p>","DOI":"10.1097\/md.0000000000035348","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:09:34Z","timestamp":1696007374000},"page":"e35348","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["An integrated mRNA\u2013lncRNA signature for overall survival prediction in cholangiocarcinoma"],"prefix":"10.1097","volume":"102","author":[{"given":"Derong","family":"Xu","sequence":"first","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zeng","sequence":"additional","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mukiibi","sequence":"additional","affiliation":[{"name":"The Roslin Institute, University of Edinburgh, Midlothian, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Xin","sequence":"additional","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-4037","authenticated-orcid":false,"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma.","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma.","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visc Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments.","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise.","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management.","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma.","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention.","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/vaccines9050422","article-title":"The emerging role of immunotherapy in intrahepatic cholangiocarcinoma.","volume":"9","author":"Fiste","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.31534","article-title":"Long noncoding RNAs in cholangiocarcinoma.","volume":"73","author":"Merdrignac","year":"2021","journal-title":"Hepatology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e848","DOI":"10.1002\/ctm2.848","article-title":"YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.","volume":"12","author":"Huang","year":"2022","journal-title":"Clin Transl Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2019.11.021","article-title":"MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR\/PI3K\/AKT pathways.","volume":"72","author":"Tiemin","year":"2020","journal-title":"J Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41419-022-05412-5","article-title":"JUND\/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202\/GPX4 axis.","volume":"13","author":"Lei","year":"2022","journal-title":"Cell Death Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41417-022-00500-2","article-title":"Exosomal lncRNA HCG18 contributes to cholangiocarcinoma growth and metastasis through mediating miR-424-5p\/SOX9 axis through PI3K\/AKT pathway.","volume":"30","author":"Ni","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1245\/s10434-013-3286-x","article-title":"Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.","volume":"21","author":"Ruys","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R17-20250504","first-page":"1422","article-title":"A novel three-miRNA signature predicts survival in cholangiocarcinoma based on RNASeq data.","volume":"40","author":"Cao","year":"2018","journal-title":"Oncol Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7150\/ijbs.38846","article-title":"Prognostic values of a novel multi-mRNA signature for predicting relapse of cholangiocarcinoma.","volume":"16","author":"Guo","year":"2020","journal-title":"Int J Biol Sci"},{"key":"R19-20250504","first-page":"8064","article-title":"ER stress-related mRNA\u2013lncRNA co-expression gene signature predicts the prognosis and immune implications of esophageal cancer.","volume":"14","author":"Li","year":"2022","journal-title":"Am J Transl Res"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"738477","DOI":"10.3389\/fonc.2021.738477","article-title":"Identification of a ferroptosis-related signature model including mRNAs and LncRNAs for predicting prognosis and immune activity in hepatocellular carcinoma.","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1101\/gr.180596.114","article-title":"The landscape of antisense gene expression in human cancers.","volume":"25","author":"Balbin","year":"2015","journal-title":"Genome Res"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4174\/astr.2019.96.4.153","article-title":"Genetic features associated with (18)F-FDG uptake in intrahepatic cholangiocarcinoma.","volume":"96","author":"Ahn","year":"2019","journal-title":"Ann Surg Treat Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2014update.","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc: Ser B (Methodological)"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"16294","DOI":"10.1038\/srep16294","article-title":"Comprehensive analysis of transcriptome and metabolome analysis in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.","volume":"5","author":"Murakami","year":"2015","journal-title":"Sci Rep"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep.25570","article-title":"A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.","volume":"55","author":"Seok","year":"2012","journal-title":"Hepatology"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma.","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.25890","article-title":"Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.","volume":"56","author":"Oishi","year":"2012","journal-title":"Hepatology"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of change point methods in studying the effect of age on survival in breast cancer.","volume":"30","author":"Piti","year":"1999","journal-title":"Comput Stati Data Analy"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks.","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis.","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS J Integr Biol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"100819","DOI":"10.18632\/oncotarget.19044","article-title":"miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA).","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"R39-20250504","first-page":"2694","article-title":"Complement factor Hrelated 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis.","volume":"20","author":"Liu","year":"2019","journal-title":"Mol Med Rep"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/jcb.29551","article-title":"CFHR3 is a potential novel biomarker for hepatocellular carcinoma.","volume":"121","author":"Liu","year":"2020","journal-title":"J Cell Biochem"},{"key":"R41-20250504","first-page":"2525","article-title":"The role of 17betaestradiolinduced upregulation of Piwilike 4 in modulating gene expression and motility in breast cancer cells.","volume":"40","author":"Heng","year":"2018","journal-title":"Oncol Rep"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s11658-017-0048-y","article-title":"PIWI-like protein, HIWI2 is aberrantly expressed in retinoblastoma cells and affects cell-cycle potentially through OTX2.","volume":"22","author":"Sivagurunathan","year":"2017","journal-title":"Cell Mol Biol Lett"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.18632\/oncotarget.13491","article-title":"Co-expression of Piwil2\/Piwil4 in nucleus indicates poor prognosis of hepatocellular carcinoma.","volume":"8","author":"Zeng","year":"2017","journal-title":"Oncotarget"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/cells9030596","article-title":"Multifaceted aspects of metabolic plasticity in human cholangiocarcinoma: an overview of current perspectives.","volume":"9","author":"Pastore","year":"2020","journal-title":"Cells"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/hepr.13386","article-title":"Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis.","volume":"49","author":"Tian","year":"2019","journal-title":"Hepatol Res"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"12755","DOI":"10.1007\/s13277-016-5186-8","article-title":"Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.","volume":"37","author":"Likhitrattanapisal","year":"2016","journal-title":"Tumour Biol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/cgt.2015.66","article-title":"Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.","volume":"23","author":"Huang","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/hep.28508","article-title":"Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2527\/jas.2015-0126","article-title":"Accuracy of genomic predictions for feed efficiency traits of beef cattle using 50K and imputed HD genotypes.","volume":"94","author":"Lu","year":"2016","journal-title":"J Anim Sci"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00795-019-00230-9","article-title":"Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.","volume":"53","author":"Nakagawa","year":"2020","journal-title":"Med Mol Morphol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s10620-005-9064-2","article-title":"A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.","volume":"51","author":"Kobuke","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/jhep.2003.50296","article-title":"PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.","volume":"38","author":"Han","year":"2003","journal-title":"Hepatology"},{"key":"R53-20250504","first-page":"867","article-title":"The PPARgamma ligand, 15-Deoxy-Delta12,14-PGJ2, regulates apoptosis-related protein expression in cholangio cell carcinoma cells.","volume":"12","author":"Okano","year":"2003","journal-title":"Int J Mol Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:39:51Z","timestamp":1746326391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":51,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035348","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}